ACOD1 and cancer: The combination of Irg1 deficiency and PD-1/PD-L1 blockade can collaborate to enhance the antitumor immunity, suggesting that targeting ACOD1 can be effective and convenient for monotherapy as well as adjuvant therapy with current PD-(L)1 blockades for treating different cancer types.